Omico is changing the way we fight cancer.
We are an independent, not-for-profit, organisation providing Australians with equitable, accelerated access to cutting-edge, proven precision oncology. Our role is to translate the latest scientific innovations into meaningful advances in clinical care, health policy and system reform, ensuring science delivers real-world benefit for patients. We unite Australia’s leading cancer institutes, researchers, clinicians, industry partners, advocacy groups and government to facilitate a new way to tackle our most challenging cancers. By harnessing a nationwide network of expertise, infrastructure and resources, we aim to improve outcomes for Australian cancer patients. By fast tracking molecular and genomic profiling, biomarker-led clinical trials and patient enrolment across the country, Omico is enabling access to next-generation treatments and preventive strategies for those who need them most.
What we do
We aim to improve outcomes for Australians by:
- Expanding access to precision oncology through comprehensive genomic profiling and treatment matching, helping identify potential clinical trial and treatment options.
- Growing and streamlining biomarker-led clinical trials by accelerating patient enrolment and site activation, supporting drug development, enabling faster transitions from discovery to clinical application, and attracting more international trials to Australia to open new treatment pathways for patients
- Opening new treatment pathways for patients through access to emerging precision oncology trials and therapies.
- Advancing personalised cancer risk management by using heritable genetic information to assess cancer predisposition and guide clinical risk management.
- Generating real world data using patient-centred evidence to support research, inform policy and help improve health systems and clinical cancer care.
- Accelerating collaboration and research by working with local and global partners to fuel research and strengthen Australia’s cancer ecosystem.
Who we work with
Recent news
Omico expands access to unique, real-world data offering
Sydney Australia – 2 June 2026 - Omico is expanding its contribution to the national precision oncology ecosystem with the launch of a new real-world data (RWD) initiative designed to advance cancer research, clinical development and future innovations in precision cancer care.
Federal Government commits $71M to life-extending precision oncology
Sydney Australia – 12 May 2026 – $71 million Federal Government investment will support Omico’s national precision oncology program PrOSPeCT 2.0*, until 2028/29.
New JAMA Oncology study shows improved survival through Omico’s MoST precision oncology program
Sydney, Australia - 5 March 2026 - A new peer-reviewed study published in JAMA Oncology shows that patients with advanced cancers lived significantly longer when their treatment was matched to genomic biomarkers using strong clinical trial evidence — highlighting how precision oncology can deliver real benefit for patients.